CASP3 and prostate cancer: A decreased BCL2/BAX ratio, together with increased caspase-3 activity and protein abundance were observed in PC-3, DU-145 and LNCaP prostate cancer cells after using CAPE synergistically with docetaxel and paclitaxel.